Invitae Prices $400M Common Stock Offering

Jan 22, 2021

|

NEW YORK – Invitae said after the close of the market on Thursday that it has priced an underwritten public offering of 7,766,990 shares of its common stock at $51.50 per share.

The molecular diagnostics firm expects gross proceeds of approximately $400 million from the offering, which it announced on Wednesday. Invitae has also granted underwriters a 30-day option to purchase an additional 1,165,048 shares of its common stock at the public offering price.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

More Details Wanted

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

And a Third

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Glimpses of Viral Origins

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

PLOS Papers on Plasmodium Falciparum Populations, Scabies Molecular Diagnostics, More

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Featured White Papers

Congenica Enables Five Minute Diagnosis of Previously Unsolved Case

Congenica CNV Calling for Exomes Whitepaper

Congenica Splice Site Finder White Paper

Expediting an Accurate Diagnosis through Streamlined Clinical Workflows

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

16

Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community.

Mar

17

Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Menu

Invitae Prices $400M Common Stock Offering

To read the full story....

Breaking News

OraSure Technologies Q4 Revenues Rise 27 Percent, Beat Analysts' Estimate

NanoString Technologies Q4 Revenues Fall 2 Percent

Host DNA Methylation Signatures May Predict Likelihood of Persistent, Resolving MRSA Infections

Seqster, Medable Team on Data Integration for Clinical Trials

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

The Scan

More Details Wanted

And a Third

Glimpses of Viral Origins

PLOS Papers on Plasmodium Falciparum Populations, Scabies Molecular Diagnostics, More

Featured White Papers

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

What's Popular?

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

GenMark Diagnostics Seeing Continued Demand for Respiratory Panels, Plans 510(k) Submission

Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Sponsorships